Status:
COMPLETED
Evaluation of the Role of Neurodegeneration in Schizophrenia
Lead Sponsor:
Istanbul Saglik Bilimleri University
Conditions:
Schizophrenia
Eligibility:
All Genders
18-65 years
Brief Summary
Schizophrenia is a progressive psychiatric disorder with a lifetime prevalence of 1%, its etiology is not fully understood, and it progresses with relapses. There are significant differences between p...
Detailed Description
Schizophrenia is a progressive and complex psychiatric disorder with a lifetime prevalence of 1%, usually diagnosed between the ages of 20-25, its etiology is not fully understood, and it progresses w...
Eligibility Criteria
Inclusion
- Inclusion Criteria for Patients
- Being between the ages of 18-65
- Being at least primary school graduate
- Not having mental retardation
- Not having visual and hearing problems that affect communication
- Having a diagnosis of schizophrenia according to DSM-5 criteria
- Absence of comorbid psychiatric disease
- Systemic and/or systemic disease. or neurological (such as hypertension, diabetes mellitus, infection, dementia, epilepsy, Parkinson's disease, cardiovascular, renal, urological, hepatic, pulmonary, genetic, endocrine diseases, nutritional disorders, intoxications, operations, and other organic disorders), S100B and GFAP levels No medical condition known to affect it
- No history of head trauma
- No alcohol and/or substance use disorder
- Body mass index (BMI) \> 18 kg/m2 , BMI \< 25 kg/m2
- Not having been diagnosed with metabolic syndrome
- 1\. and/or No 2nd degree relatives with schizophrenia and/or a similar psychiatric disorder
- After being informed about the study,
- Inclusion Criteria for Healthy Controls
- Being between the ages of 18-65
- Being at least primary school graduate
- Not having mental retardation
- Not having vision and hearing problems that affect communication
- Among first and/or second degree relatives No history of schizophrenia and/or any other psychiatric disease
- Systemic and/or neurological (hypertension, diabetes mellitus, infection, dementia, epilepsy, parkinson's disease, cardiovascular, renal, urological, hepatic, pulmonary, genetic, endocrine diseases, nutritional disorders, intoxications , operations and other organic disorders), absence of medical conditions known to adversely affect S1000B and GFAP levels
- No history of head trauma
- No alcohol and/or substance use disorder
- Body mass index (BMI)\> 18 kg/m2 , \< 25 kg/ m2
- Not having been diagnosed with metabolic syndrome
- Having a 1st and/or 2nd degree relatives with schizophrenia and/or similar No psychiatric disorder
- Having consented to participate in the study after being informed about the study Exclusion Criteria
- Not between the ages of 18-65
- Having a diagnosis of mental retardation
- Having vision and/or hearing problems that affect communication
- Presence of psychiatric illness
- First and/or second degree relatives between schizophrenia and/or another psychiatric disease diagnosis
- Systemic and/or neurological (hypertension, diabetes mellitus, infection, dementia, epilepsy, parkinson's disease, cardiovascular, renal, urological, hepatic, pulmonary, genetic, endocrine diseases, nutritional disorders, intoxications, operations and other organic disorders), presence of medical conditions known to adversely affect S100B and GFAP levels
- Presence of non-psychiatric drug use
- Presence of head trauma
- Presence of alcohol and/or substance use disorder
- Body mass index (BMI) \> 25 kg /m2
- Metabolic syndrome being diagnosed as Having schizophrenia and/or a similar psychiatric disorder in 1st and/or 2nd degree relatives
- After being informed about the study, the patient and/or his guardian or healthy control did not give consent to participate in the study.
Exclusion
Key Trial Info
Start Date :
March 28 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2022
Estimated Enrollment :
178 Patients enrolled
Trial Details
Trial ID
NCT05257720
Start Date
March 28 2022
End Date
October 1 2022
Last Update
October 28 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
T.C. Sağlik Bilimleri Üniversitesi
Istanbul, Turkey (Türkiye), 34876